BSW Wealth Partners Has $707,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

BSW Wealth Partners raised its position in Boston Scientific Co. (NYSE:BSX) by 3.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 7,920 shares of the medical equipment provider’s stock after acquiring an additional 267 shares during the period. BSW Wealth Partners’ holdings in Boston Scientific were worth $707,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Patriot Financial Group Insurance Agency LLC increased its stake in Boston Scientific by 12.3% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 15,410 shares of the medical equipment provider’s stock valued at $1,376,000 after purchasing an additional 1,692 shares in the last quarter. Stonegate Investment Group LLC raised its holdings in shares of Boston Scientific by 1.6% in the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider’s stock worth $699,000 after acquiring an additional 126 shares during the last quarter. Greenup Street Wealth Management LLC bought a new position in Boston Scientific in the 4th quarter valued at about $1,634,000. BankPlus Wealth Management LLC acquired a new position in Boston Scientific during the 4th quarter valued at about $262,000. Finally, Nilsine Partners LLC raised its stake in shares of Boston Scientific by 9.0% in the fourth quarter. Nilsine Partners LLC now owns 5,285 shares of the medical equipment provider’s stock worth $472,000 after purchasing an additional 437 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 14,010 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the transaction, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,989 shares of company stock valued at $2,702,261. Company insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BSX. Sanford C. Bernstein upped their price target on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Mizuho boosted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Citigroup upped their price objective on shares of Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research report on Friday, January 10th. Finally, Morgan Stanley increased their price target on Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research report on Thursday, October 24th. Three analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.26.

Boston Scientific Trading Up 0.1 %

Shares of BSX opened at $102.41 on Wednesday. Boston Scientific Co. has a twelve month low of $60.78 and a twelve month high of $102.93. The stock has a market cap of $150.93 billion, a PE ratio of 84.63, a P/E/G ratio of 2.63 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The business’s 50-day moving average price is $92.50 and its 200-day moving average price is $85.63.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.